Il valore prognostico dei biomarker sierici nell’osteosarcoma

Title

Code

ProOsteo

Type

Osservazionale

Start Year

2021

Status

Terminato

Principal Investigator

051-6366103

costantino.errani@ior.it

Errani Costantino, MD, PhD

3rd Orthopaedic and Traumatologic Clinic prevalently Oncologic

Operational unit that carry out the study

complex unit

Clinica Ortopedica e Traumatologica III a prevalente indirizzo Oncologico

Director

Donati Davide Maria, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio osservazionale ProOsteo

Wednesday 27 July 2022, 14:15

PG0010471_2021_ProOsteo.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

Sito Web Istituto Ortopedico Rizzoli

DIPARTIMENTO RIZZOLI-SICILIA

Il valore prognostico dei biomarker sierici nell’osteosarcoma

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in